However, in pancreatic ductal adenocarcinoma (PDAC) there are only four abundantly common driver mutations (KRAS,CDKN2A,TP53, and SMAD4), which are not currently actionable. This evidence concerns the gene KRAS and pancreatic ductal adenocarcinoma.